Skip to main content
. 2017 May 18;12(5):e0177600. doi: 10.1371/journal.pone.0177600

Table 1. The suppressive effects of zacopride pretreatment or post-treatment on acute ischemic arrhythmias in anesthetized rats in vivo (mean ± SEM).

n Arrhythmia latency time (s) Total episodes of PVC Duration of VT (s) Incidence of VT (%) Duration of VF (s) Incidence of VF (%)
Pretreatment
 Control 8 344.1 ± 21.1 149 ± 23 51.2 ± 16.1 100 6.9 ± 2.5 75
 Zac 5 μg/kg 8 394.3 ± 18.2 157 ± 13 40.4 ± 5.2 100 0.7 ± 0.7 ** 12.5 *
 Zac 15 μg/kg 8 475.6 ± 35.0 ** 45 ± 15** 2.1 ± 1.4** 25** 0 ** 0 **
 Zac 50 μg/kg 8 402.6 ± 36.7 38 ± 12** 9.2 ± 2.9** 75 0.2 ± 0.2 ** 12.5 *
 Lidoc 7.5 mg/kg 8 518.8 ± 27.8 **# 57 ± 17**# 1.2 ± 0.9**# 25**# 0.2 ± 0.2 **# 12.5 *#
Post-treatment
 Control 8 335.6 ± 11.8 105 ± 18 51.9 ± 12.3 100 4.4 ± 1.7 75
 Zac 15 μg/kg 8 447.1 ± 26.1 ** 14 ± 5** 1.8 ± 0.9** 37.5* 0 ** 0**
 Lidoc 7.5 mg/kg 8 430.6 ± 20.9**# 53 ± 19**# 1.8 ± 1.0**# 50# 0.3 ± 0.3 **# 12.5 *#

PVC, premature ventricular contraction. VT, ventricular tachycardia. VF, ventricular fibrillation. Zac, zacopride. Lidoc, lidocaine. Duration of VT, mean episode duration of VT. Duration of VF, mean episode duration of VF.

* P < 0.05,

** P < 0.01 vs. control.

# P > 0.05 vs. 15 μg/kg Zac.